A group of investigators led by Cedars-Sinai have developed and successfully tested a new artificial intelligence method to make launching cancer clinical trials easier and faster. The method uses patients’ pathology reports to automate the classification of patients by the severity of their cancers, potentially shortening the process of selecting candidates for clinical trials.
Ze’ev Ronai, a cancer investigator and director of the Translational Research Institute at Cedars-Sinai, received an Outstanding Investigator Award from NCI.
